Science

what-turns-a-fungal-scavenger-into-a-killer?

What turns a fungal scavenger into a killer?

fungus, gene activity, molecular biology, Science / /

Fungus feeding —

Beware the sticky, tricky genetic weapons of a fungal carnivore.

–

greyscale microscope image of a long, thin, unsegmented worm.

Enlarge / The fungus’ favorite food.

Some of the scariest monsters are microscopic. The carnivorous fungus Arthrobotrys oligospora doesn’t seem like much while it’s eating away at rotting wood. But when it senses a live worm, it will trap its victim and consume it alive—pure nightmare fuel.

Until now, not much was known about how the attack of the killer fungus happens on a molecular level. Researchers from Academia Sinica in Taiwan have finally found out how the gene activity of the fungus changes when a nematode creeps too close to A. oligospora. Led by molecular biologist Hung-Che Lin, the research team discovered that the fungus synthesizes a sort of worm adhesive and additional trapping proteins to get ahold of its meal. It then produces enzymes that break down the worm so it can start feasting.

Caught in a trap

A. oligospora lives in the soil and is mostly saprotrophic, meaning it feeds on decaying organic matter. But that can quickly change if it finds itself deprived of nutrients or senses a tempting nematode nearby. This is when it goes into carnivore mode.

Lin and his colleagues wanted to see what happened when the fungus, low on nutrients, was introduced to the nematode Caenorhabiditis elegans. The fungus showed a significant increase in DNA replication when it sensed the worm. This resulted in trap cells having additional copies of the genome. The trap cells reside in fungal filaments, or hyphae, and produce a specialized worm adhesive that would allow those hyphae to stick to the worm once it was caught in the trap.

What may be the most important genetic actions in helping the fungus to create a trap out of hyphae is ribosome biogenesis, which enables increased protein production. Ribosomes are where proteins are made, so their biogenesis (literally the creation of more ribosomes) controls cell growth and also determines how much protein is synthesized.

The researchers also identified a new group of proteins, now known as Trap Enriched Proteins (TEPs), which were the most commonly produced proteins in fungal trap cells. These seemed to contribute to trap function rather than formation.

“Given TEP protein localization to the surface of trap cells, we hypothesized that TEPs may be critical for the function of the traps,” they said in a study recently published in PLoS Biology. “Adding C. elegans… leads to their immediate capture.”

As the fungus put more effort into creating a trap and forming worm adhesive, it deprioritized activities that are not really involved in the process. Segments of DNA that usually help A. oligospora digest dead matter were down-regulated, meaning there was lower gene activity on these segments in response to the fungus sensing the worm. When a worm came close to A. oligospora, the fungus showed an up-regulation of genes that produce proteases, or enzymes that break down proteins.

Can’t get out

Additional other genes didn’t see changes in activity until the worm was already caught. Once C. elegans entered the trap that A. oligospora had set with a sticky net of hyphae, the team noticed an increase in the production of proteins that weaken prey. These proteins are able to manipulate the cells of their prey so those cells function differently, potentially providing a way for the pathogen to break in and take over. The fungus then uses proteases to digest nematodes that get stuck in its hyphae.

A. oligospora has over 400 genes that encode proteins that control its interactions with other organisms. When the introduction of a nematode made the fungus go carnivorous, more than half of these started to behave differently. These proteins weaken C. elegans through a variety of mechanisms. To give one example, some of them fight off antimicrobial peptides produced by the nematode.

The adhesive synthesized by the fungus, now thought to have a close association with TEP proteins, may have no effect on humans but is a superglue for worms that binds hyphae to their flesh. They have no way of worming their way out of being eaten alive.

This experiment might have been ghastly for the nematodes involved, but it was a breakthrough for Lin’s team. They have now identified an entire new group of genes that make a fungal trap function. Their findings with A. oligospora could be compared to the gene activity of other pathogenic fungi, including those that destroy crops, so an improved generation of antifungals might someday be influenced by this microscopic horror movie.

PLOS Biology, 2023.  DOI: 10.1371/journal.pbio.3002400

What turns a fungal scavenger into a killer? Read More »

daily-telescope:-tracking-the-sun’s-path-every-day-across-the-sky

Daily Telescope: Tracking the Sun’s path every day across the sky

daily telescope, Science, Space / /

On the horizon —

The image is a vivid demonstration of the changing of the seasons.

–

The path of the Sun over Germany.

Enlarge / The path of the Sun over Germany.

Frank Niessen/IAU OAE

Welcome to the Daily Telescope. There is a little too much darkness in this world and not enough light, a little too much pseudoscience and not enough science. We’ll let other publications offer you a daily horoscope. At Ars Technica, we’re going to take a different route, finding inspiration from very real images of a universe that is filled with stars and wonder.

Good morning. It’s December 18, and today’s photo is an homage to the forthcoming winter solstice—which will visit the Northern Hemisphere on Thursday evening.

This image was a second-place finisher in a recent competition by the International Astronomical Union’s Office of Education. This year’s contest welcomed astrophotography enthusiasts at all skill levels, including images taken with smartphones.

The image, created by Frank Niessen, was captured in Germany between the summer solstice and winter solstice in 2018. It combines images taken at different times of day over the course of six months, and each curve tracks the Sun’s path across the sky on a particular day. Gaps indicate cloudy days. The image was captured using a simple pinhole camera fashioned from a coffee can. I find the effect stunning.

Stay warm out there in the Northern Hemisphere, y’all.

Source: Frank Niessen

Do you want to submit a photo for the Daily Telescope? Reach out and say hello.

Daily Telescope: Tracking the Sun’s path every day across the sky Read More »

this-“smoking-gun”-killed-the-mcdonald’s-ice-cream-hackers’-startup

This “smoking gun” killed the McDonald’s ice cream hackers’ startup

DMCA, DMCA abuse, ice cream, mcdonalds, Policy, Science, syndication / /
Vanilla Soft Serve Ice Cream Cone

A little over three years have passed since McDonald’s sent out an email to thousands of its restaurant owners around the world that abruptly cut short the future of a three-person startup called Kytch—and with it, perhaps one of McDonald’s best chances for fixing its famously out-of-order ice cream machines.

Until then, Kytch had been selling McDonald’s restaurant owners a popular Internet-connected gadget designed to attach to their notoriously fragile and often broken soft-serve McFlurry dispensers, manufactured by McDonald’s equipment partner Taylor. The Kytch device would essentially hack into the ice cream machine’s internals, monitor its operations, and send diagnostic data over the Internet to an owner or manager to help keep it running. But despite Kytch’s efforts to solve the Golden Arches’ intractable ice cream problems, a McDonald’s email in November 2020 warned its franchisees not to use Kytch, stating that it represented a safety hazard for staff. Kytch says its sales dried up practically overnight.

Now, after years of litigation, the ice-cream-hacking entrepreneurs have unearthed evidence that they say shows that Taylor, the soft-serve machine maker, helped engineer McDonald’s Kytch-killing email—kneecapping the startup not because of any safety concern, but in a coordinated effort to undermine a potential competitor. And Taylor’s alleged order, as Kytch now describes it, came all the way from the top.

On Wednesday, Kytch filed a newly unredacted motion for summary adjudication in its lawsuit against Taylor for alleged trade libel, tortious interference, and other claims. The new motion, which replaces a redacted version from August, refers to internal emails Taylor released in the discovery phase of the lawsuit, which were quietly unsealed over the summer. The motion focuses in particular on one email from Timothy FitzGerald, the CEO of Taylor parent company Middleby, that appears to suggest that either Middleby or McDonald’s send a communication to McDonald’s franchise owners to dissuade them from using Kytch’s device.

“Not sure if there is anything we can do to slow up the franchise community on the other solution,” FitzGerald wrote on October 17, 2020. “Not sure what communication from either McD or Midd can or will go out.”

In their legal filing, the Kytch co-founders, of course, interpret “the other solution” to mean their product. In fact, FitzGerald’s message was sent in an email thread that included Middleby’s then COO, David Brewer, who had wondered earlier whether Middleby could instead acquire Kytch. Another Middleby executive responded to FitzGerald on October 17 to write that Taylor and McDonald’s had already met the previous day to discuss sending out a message to franchisees about McDonald’s lack of support for Kytch.

But Jeremy O’Sullivan, a Kytch co-founder, claims—and Kytch argues in its legal motion—that FitzGerald’s email nonetheless proves Taylor’s intent to hamstring a potential competitor. “It’s the smoking gun,” O’Sullivan says of the email. “He’s plotting our demise.”

Although FitzGerald’s email doesn’t actually order anyone to act against Kytch, the company’s motion argues that Taylor played a key role in what happened next. It’s an “ambiguous yet direct message to his underlings,” argues Melissa Nelson, Kytch’s other co-founder. “It’s just like a mafia boss giving coded instructions to his team to whack someone.”

On November 2, 2020, a little over two weeks after FitzGerald’s open-ended suggestion that perhaps a “communication” from McDonald’s or Middleby to franchisees could “slow up” adoption of “the other solution,” McDonald’s sent out its email blast cautioning restaurant owners not to use Kytch’s product.

The email stated that the Kytch gadget “allows complete access to all aspects of the equipment’s controller and confidential data”—meaning Taylor’s and McDonald’s data, not the restaurant owners’ data; that it “creates a potential very serious safety risk for the crew or technician attempting to clean or repair the machine”; and finally, that it could cause “serious human injury.” The email concluded with a warning in italics and bold: “McDonald’s strongly recommends that you remove the Kytch device from all machines and discontinue use.”

This “smoking gun” killed the McDonald’s ice cream hackers’ startup Read More »

daily-telescope:-one-of-the-most-stunning-andromeda-photos-i’ve-ever-seen

Daily Telescope: One of the most stunning Andromeda photos I’ve ever seen

daily telescope, Science, Space / /

Gorgeous galaxy —

The image is the result of 100 hours of observing.

–

The Andromeda Galaxy.

Enlarge / The Andromeda Galaxy.

The Association of Widefield Astrophotographers

Welcome to the Daily Telescope. There is a little too much darkness in this world and not enough light, a little too much pseudoscience and not enough science. We’ll let other publications offer you a daily horoscope. At Ars Technica, we’re going to take a different route, finding inspiration from very real images of a universe that is filled with stars and wonder.

Good morning. It’s December 15, and I have a real treat for you today. This is an image of the Andromeda Galaxy, the nearest major galaxy to our Milky Way. Astronomers believe our galaxy is shaped much as this one is.

The photograph comes from a group that calls itself the Association of Widefield Astrophotographers, and the photo was a 100-hour project by six participants in the United States, Poland, and the United Kingdom. They collected data over several months to produce the image.

According to the organization, “Our goal with this project was to prove that very expensive equipment and dark skies aren’t required to create unique images of faint objects. Since most of us are high schoolers and college students with a passion for astronomy, our summer jobs did not allow us to afford the expensive gear used by most astrophotographers.”

Most participants worked within a city, with light pollution levels ranging from Bortle 4 to Bortle 9. While it would be difficult for an individual to reveal the faint structures in this image, they said that by working together with other astrophotographers, they could produce such a result. It is truly extraordinary.

Source: The Association of Widefield Astrophotographers

Do you want to submit a photo for the Daily Telescope? Reach out and say hello.

Daily Telescope: One of the most stunning Andromeda photos I’ve ever seen Read More »

x-ray-imaging-of-the-night-watch-reveals-previously-unknown-lead-layer

X-ray imaging of The Night Watch reveals previously unknown lead layer

art, art conservation, Dutch Golden Age, Dutch masters, operation night watch, Physics, rembrandt, Science, The Night Watch, X-Ray imaging / /

The latest from Operation Night Watch —

Rembrandt may have used lead-rich oil to prep his canvas and protect it from humidity.

–

The Nightwatch, or Militia Company of District II under the Command of Captain Frans Banninck Cocq (1642)

Enlarge / Rembrandt’s The Night Watch underwent many chemical and mechanical alterations over the last 400 years.

Public domain

Rembrandt’s The Night Watch, painted in 1642, is the Dutch master’s largest surviving painting, known particularly for its exquisite use of light and shadow. A new X-ray imaging analysis of the masterpiece has revealed an unexpected lead layer, perhaps applied as a protective measure while preparing the canvas, according to a new paper published in the journal Science Advances. The work was part of the Rijksmuseum’s ongoing Operation Night Watch, the largest multidisciplinary research and conservation project for Rembrandt’s famous painting, devoted to its long-term preservation.

The famous scene depicted in The Night Watch—officially called Militia Company of District II under the Command of Captain Frans Banninck Cocq—was not meant to have taken place at night. Rather, the dark appearance is the result of the accumulation of dirt and varnish over four centuries, as the painting was subject to various kinds of chemical and mechanical alterations.

For instance, in 1715, The Night Watch was moved to Amsterdam’s City Hall (now the Royal Palace on Dam Square). It was too large for the new location, so the painting was trimmed on all four sides, and the trimmed pieces were never found (although in 2021, AI was used to re-create the original full painting). The objective of Operation Night Watch is to employ a wide variety of imaging and analytical techniques to better understand the materials Rembrandt used to create his masterpiece and how those materials have changed over time.

As previously reported, past analyses of Rembrandt’s paintings identified many pigments the Dutch master used in his work, including lead white, multiple ochres, bone black, vermilion, madder lake, azurite, ultramarine, yellow lake, and lead-tin yellow, among others. The artist rarely used pure blue or green pigments, with Belshazzar’s Feast being a notable exception. (The Rembrandt Database is the best resource for a comprehensive chronicling of the many different investigative reports.)

Earlier this year, the researchers at Operation Night Watch found rare traces of a compound called lead formate in the painting. They scanned about half a square meter of the painting’s surface with X-ray powder diffraction mapping (among other methods) and analyzed tiny fragments from the painting with synchrotron micro X-ray probes. This revealed the presence of the lead formates—surprising in itself, but the team also identified those formates in areas where there was no lead pigment, white, or yellow. It’s possible that lead formates disappear fairly quickly, which could explain why they have not been detected in paintings by the Dutch Masters until now. But if that is the case, why didn’t the lead formate disappear in The Night Watch? And where did it come from in the first place? 

Hoping to answer these questions, the team whipped up a model of “cooked oils” from a 17th century recipe, which called for mixing and heating linseed oil and lead oxide, then adding hot water to the reacting mixture. They analyzed those model oils with synchrotron radiation. The results supported their hypothesis that the oil used for light parts of the painting was treated with an alkaline lead drier. The fact that The Night Watch was revarnished with an oil-based varnish in the 18th century complicates matters, as this may have provided a fresh source of formic acid, such that different regions of the painting rich in lead formates may have formed at different times in the painting’s history.

This latest paper sheds more light on the painting by focusing on the preparatory layers applied to the canvas. It’s known that Rembrandt used a quartz-clay ground for The Night Watch—the first time he had done so, perhaps because the colossal size of the painting “motivated him to look for a cheaper, less heavy and more flexible alternative for the ground layer” than the red earth, lead white, and cerussite he was known to use on earlier paintings, the authors suggested.

The Night Watch via the correlated synchrotron-based X-ray fluorescence and ptychographic tomography of a paint sample, supported by a macroscale X-ray fluorescence scan of the whole painting.” height=”439″ src=”https://cdn.arstechnica.net/wp-content/uploads/2023/12/nightwatch4-640×439.jpg” width=”640″>

Enlarge / A so far unknown lead-containing impregnation ‘layer’ was discovered in Rembrandt’s The Night Watch via the correlated synchrotron-based X-ray fluorescence and ptychographic tomography of a paint sample, supported by a macroscale X-ray fluorescence scan of the whole painting.

Fréderique Broers

Per the authors, this is the first time that 3D X-ray imaging techniques have been used: X-ray fluorescence and X-ray ptychographic nano-tomography applied to an embedded paint fragment comprised of only the quartz-clay ground. The authors maintain that microscale analysis of historical paintings usually relies on 2D imaging techniques (e.g., light microscopy, scanning electron microscopy, synchrotron radiation spectroscopy), which only yield partial information about the size, shape, and distribution of pigment particles below the visible surface.

The 3D methods capture more detail by comparison, revealing the presence of an unknown (and unexpected) lead-containing layer located just underneath the ground layer. The authors suggest that this could be due to using a lead compound added to the oil used to prepare the canvas as a drying additive—perhaps to protect the painting from the damaging effects of humidity. (Usually a glue sizing was used before applying the ground layer.)

The Night Watch originally hung in the “great hall” of a musketeer shooting range in Amsterdam and faced windows. The authors note that since the Middle Ages, red lead in oil has been used to preserve stone, wood, and metal against humidity, and one contemporary source mentions using lead-rich oil instead of the typical glue to keep the canvas from separating after years of exposure in humid environments. And that newly discovered lead layer could be the reason for the unusual lead protrusions in areas of The Night Watch with no other lead-containing compounds in the paint. It’s possible that lead migrated into the painting’s ground layer from that lead-oil preparatory layer below.

DOI: Science Advances, 2023. 10.1126/sciadv.adj9394  (About DOIs).

X-ray imaging of The Night Watch reveals previously unknown lead layer Read More »

if-ai-is-making-the-turing-test-obsolete,-what-might-be-better?

If AI is making the Turing test obsolete, what might be better?

AI, Computer science, Science, Turing test / /
A white android sitting at a table in a depressed manner with an alchoholic drink. Very high resolution 3D render.

If a machine or an AI program matches or surpasses human intelligence, does that mean it can simulate humans perfectly? If yes, then what about reasoning—our ability to apply logic and think rationally before making decisions? How could we even identify whether an AI program can reason? To try to answer this question, a team of researchers has proposed a novel framework that works like a psychological study for software.

“This test treats an ‘intelligent’ program as though it were a participant in a psychological study and has three steps: (a) test the program in a set of experiments examining its inferences, (b) test its understanding of its own way of reasoning, and (c) examine, if possible, the cognitive adequacy of the source code for the program,” the researchers note.

They suggest the standard methods of evaluating a machine’s intelligence, such as the Turing Test, can only tell you if the machine is good at processing information and mimicking human responses. The current generations of AI programs, such as Google’s LaMDA and OpenAI’s ChatGPT, for example, have come close to passing the Turing Test, yet the test results don’t imply these programs can think and reason like humans.

This is why the Turing Test may no longer be relevant, and there is a need for new evaluation methods that could effectively assess the intelligence of machines, according to the researchers. They claim that their framework could be an alternative to the Turing Test. “We propose to replace the Turing test with a more focused and fundamental one to answer the question: do programs reason in the way that humans reason?” the study authors argue.

What’s wrong with the Turing Test?

During the Turing Test, evaluators play different games involving text-based communications with real humans and AI programs (machines or chatbots). It is a blind test, so evaluators don’t know whether they are texting with a human or a chatbot. If the AI programs are successful in generating human-like responses—to the extent that evaluators struggle to distinguish between the human and the AI program—the AI is considered to have passed. However, since the Turing Test is based on subjective interpretation, these results are also subjective.

The researchers suggest that there are several limitations associated with the Turing Test. For instance, any of the games played during the test are imitation games designed to test whether or not a machine can imitate a human. The evaluators make decisions solely based on the language or tone of messages they receive. ChatGPT is great at mimicking human language, even in responses where it gives out incorrect information. So, the test clearly doesn’t evaluate a machine’s reasoning and logical ability.

The results of the Turing Test also can’t tell you if a machine can introspect. We often think about our past actions and reflect on our lives and decisions, a critical ability that prevents us from repeating the same mistakes. The same applies to AI as well, according to a study from Stanford University which suggests that machines that could self-reflect are more practical for human use.

“AI agents that can leverage prior experience and adapt well by efficiently exploring new or changing environments will lead to much more adaptive, flexible technologies, from household robotics to personalized learning tools,” Nick Haber, an assistant professor from Stanford University who was not involved in the current study, said.

In addition to this, the Turing Test fails to analyze an AI program’s ability to think. In a recent Turing Test experiment, GPT-4 was able to convince evaluators that they were texting with humans over 40 percent of the time. However, this score fails to answer the basic question: Can the AI program think?

Alan Turing, the famous British scientist who created the Turing Test, once said, “A computer would deserve to be called intelligent if it could deceive a human into believing that it was human.” His test only covers one aspect of human intelligence, though: imitation. Although it is possible to deceive someone using this one aspect, many experts believe that a machine can never achieve true human intelligence without including those other aspects.

“It’s unclear whether passing the Turing Test is a meaningful milestone or not. It doesn’t tell us anything about what a system can do or understand, anything about whether it has established complex inner monologues or can engage in planning over abstract time horizons, which is key to human intelligence,” Mustafa Suleyman, an AI expert and founder of DeepAI, told Bloomberg.

If AI is making the Turing test obsolete, what might be better? Read More »

mdma—aka-ecstasy—submitted-to-fda-as-part-of-ptsd-therapy

MDMA—aka ecstasy—submitted to FDA as part of PTSD therapy

fda, health, maps, mdma, psychedelics, PTSD, Science, therapy / /

Groovy —

If FDA approved, it would require the DEA to reclassify MDMA.

–

Girl with an ecstasy tablet on her tongue.

Enlarge / Girl with an ecstasy tablet on her tongue.

A corporation dedicated to studying the benefits of psychedelic drugs filed an application with the Food and Drug Administration this week for approval to use MDMA—aka ecstasy or molly—in combination with talk therapy to treat post-traumatic stress disorder.

If approved, it would be the first-of-its-kind combination treatment—a psychedelic-assisted therapy. An approval would also require the Drug Enforcement Administration to reclassify MDMA, which is currently in the DEA’s most restricted category, Schedule I, which is defined as drugs “with no currently accepted medical use and a high potential for abuse.” The category also includes LSD, heroin, and marijuana.

The public benefit corporation (PBC) that filed the FDA application was created by MAPS, The Multidisciplinary Association for Psychedelic Studies, which has been supporting this type of work since 1986. The application is based on positive data from two randomized, double-blind, placebo-controlled Phase III studies, which were funded and organized by MAPS and MAPS PBC.

The first study, published in Nature Medicine in 2021, involved a total of 90 participants with moderate PTSD. It found that MDMA-assisted talk therapy (aka psychotherapy) significantly improved Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) scores compared with participants who were given talk therapy with a placebo. In the second study, published in September in Nature Medicine, the finding held up among 104 participants with moderate or severe PTSD (73 percent had severe PTSD).

In both trials, participants took 80 to 180 mg doses of MDMA or a placebo at the start of three eight-hour sessions, which were spaced around a month apart. Between those experimental treatment sessions, participants also had three 90-minute sessions for participants to process the experimental experience.

MDMA—3,4-methylenedioxymethamphetamine—affects neurotransmitters in the brain, increasing the activity of serotonin, dopamine, and norepinephrine, to be specific. This leads people who take the drug to experience euphoria, hallucinations, sharpened sensory perception, and sociability, but it can also induce confusion, depression, and paranoia. Its use in psychotherapy has been explored for decades.

In a statement this week, MAPS PBC CEO Amy Emerson celebrated the FDA submission. “The filing of our [new drug application] is the culmination of more than 30 years of clinical research, advocacy, collaboration, and dedication to bring a potential new option to adults living with PTSD, a patient group that has experienced little innovation in decades,” she said.

MAPS founder and President Rick Doblin also celebrated the submission this week, saying in a statement: “When I started MAPS in 1986, the FDA was still blocking all research with psychedelics. … By breaking that barrier, we have opened doors for others to conduct their own promising research into psychedelic-assisted therapies with psilocybin, ayahuasca, ketamine, and more. The novel approaches undertaken in psychedelic-assisted therapy research have led to fundamental shifts in our understanding of how these devastating mental health conditions can be treated.”

So far, the MDMA-assisted therapy has drawn criticism for its expected inaccessibility. The treatment outlined in the two MDMA trials involves lengthy—and likely pricey—therapy sessions with highly trained therapists. The Washington Post published an estimated price of between $13,000 to $15,000 per treatment round, and it’s unclear for now whether it would be covered by health insurance if approved by the FDA. “Most people in the world won’t be able to afford these clinics,” Allen Frances, a Duke University professor emeritus of psychiatry, told the Post.

Now that the NDA is submitted, the FDA has 60 days to determine whether it will be accepted for review and whether it will be a priority or standard review (six months or ten months, respectively), MAPS PBS noted. MAPS is seeking a priority review. In 2017, the FDA granted MDMA “Breakthrough Therapy,” designed to help hasten the development and review of drugs for serious conditions when evidence indicates they may substantially improve upon current therapies.

The only psychedelic with FDA approval to date is esketamine, a variation of ketamine, which was approved in 2019 to treat treatment-resistant depression.

MDMA—aka ecstasy—submitted to FDA as part of PTSD therapy Read More »

jeff-bezos-says-what-we’re-all-thinking:-“blue-origin-needs-to-be-much-faster”

Jeff Bezos says what we’re all thinking: “Blue Origin needs to be much faster”

blue origin, Jeff Bezos, Science, Space / /

Orbit, finally? —

“We’re going to become the world’s most decisive company across any industry.”

–

Jeff Bezos holding aviation glasses up to his face.

Enlarge / Jeff Bezos, shortly after he rode on New Shepard to space.

Joe Raedle/Getty Images

Amazon founder Jeff Bezos gives very few interviews, but he recently sat down with the computer scientist and podcaster Lex Fridman for a two-hour interview about Amazon, Blue Origin, his business practices, and more.

The discussion meanders somewhat, but there are some interesting tidbits about spaceflight, especially when the conversation turns to Blue Origin. This is the space company Bezos founded more than 23 years ago. He has invested an extraordinary amount of money into Blue Origin—likely somewhere between $10 billion and $20 billion—and it truly is a passion project.

But the inescapable truth about Blue Origin is that to date, it has been a disappointment in terms of execution. At present, Blue Origin employs approximately 11,000 people, about the same total as SpaceX. However, Blue Origin has launched zero rockets this year, whereas SpaceX has launched nearly 100, as well as building and launching thousands of satellites.

During the interview, Bezos candidly acknowledged this. “Blue Origin needs to be much faster, and it’s one of the reasons that I left my role as the CEO of Amazon a couple of years ago,” he said. “I wanted to come in, and Blue Origin needs me right now. Adding some energy, some sense of urgency. We need to move much faster. And we’re going to.”

Becoming a decisive company

How is Blue Origin going to speed up?

“We’re going to become the world’s most decisive company across any industry,” he said. “We’re going to get really good at taking appropriate technology risks, making those decisions quickly. You know, being bold on those things. And having the right culture that supports that. You need people to be ambitious, technically ambitious. If there are five ways to do something, we’ll study them, but let’s go through them very quickly and make a decision. We can always change our mind.”

When discussing Blue Origin, it’s almost impossible not to compare the company to SpaceX, which also has a prominent billionaire founder, Elon Musk. Bezos’ comments about being decisive are striking because that is one of the secrets to SpaceX’s success. During technical meetings, Musk will make a decision and accept the responsibility for that decision when it comes to key questions. Then, without hesitation, the company moves down that path until it finds success or realizes it has followed the wrong path and course-corrects.

The key is to make a decision, try something, and move on. Decisiveness is the antithesis of how many corporations make decisions, with multiple layers of middle management, or government agencies and their endless committees and meetings.

Bezos recently got rid of Bob Smith, who had served as Blue Origin’s CEO for half a decade. Smith’s tenure was marked by tentativeness. Now that Bezos has hired Dave Limp, a former Amazon executive to run Blue Origin, this move toward decisiveness could help Blue Origin move faster.

The company may finally be on the cusp of tangible results. During the interview, Bezos said he was optimistic about finally reaching orbit. The company’s large New Glenn rocket is nearing readiness, and Bezos did not seek to dampen expectations. “I’m very optimistic that the first launch of new Glenn will be in 2024,” he said. This echoes comments Ars reported on from another Blue Origin official, Lars Hoffman, earlier this week.

What does he think about Musk?

Bezos said a lot of the company’s focus has been not just on getting the first New Glenn rocket ready at Blue Origin’s factory in Florida but on building up the capacity to fly two dozen a year. “Rate manufacturing is at least as difficult as designing the vehicle in the first place,” he said.

This includes building two dozen upper stages—each of which is powered by two BE-3U engines—a year because second-stage reuse is not in the company’s immediate plans.

“We’re going to work on manufacturing that second stage to make it as inexpensive as possible,” Bezos said. “There are two paths for a second stage: make it reusable or work really hard to make it inexpensive so you can afford to expend it. And that trade is actually not obvious which one is better.” In his remarks, Bezos did not reference the company’s experiments with an experimental reusable upper stage called Project Jarvis.

Bezos also took the high road when asked about Musk, who has puerilely suggested before that Bezos “couldn’t get it up” because Blue Origin lacked an orbital rocket.

“Well, I don’t really know Elon very well,” Bezos said. “I know his public persona. But I also know you can’t know anyone by their public persona. It’s impossible. I mean, you may think you do, but I guarantee you don’t. In terms of judging him by the results, he must be a very capable leader. There’s no way you could have Tesla and SpaceX without being a capable leader. It’s impossible.”

Jeff Bezos says what we’re all thinking: “Blue Origin needs to be much faster” Read More »

what-happens-in-a-crow’s-brain-when-it-uses-tools? 

What happens in a crow’s brain when it uses tools? 

Behavioral science, Biology, birds, Crows, neurobiology, Science, tool use / /

This is your brain on tools —

Researchers trace the areas of the brain that are active when birds are using tools.

–

Three crows on the streets in the foreground with traffic and city lights blurry in the background.

Enlarge / Sure, they can use tools, but do they know where the nearest subway stop is?

“A thirsty crow wanted water from a pitcher, so he filled it with pebbles to raise the water level to drink,” summarizes a famous Aesop Fable. While this tale is thousands of years old, animal behaviorists still use this challenge to study corvids (which include crows, ravens, jays, and magpies) and their use of tools. In a recent Nature Communications study, researchers from a collaboration of universities across Washington, Florida, and Utah used radioactive tracers within the brains of several American crows to see which parts of their brains were active when they used stones to obtain food from the bottom of a water-filled tube.

Their results indicate that the motor learning and tactile control centers were activated in the brains of the more proficient crows, while the sensory and higher-order processing centers lit up in the brains of less proficient crows. These results suggest that competence with tools is linked to certain memories and muscle control, which the researchers claimed is similar to a ski jumper visualizing the course before jumping.

The researchers also found that out of their avian test subjects, female crows were especially proficient at tool usage, succeeding in the challenge quickly. “[A] follow-up question is whether female crows actually have more need for creative thinking relative to male crows,” elaborates Loma Pendergraft, the study’s first author and a graduate student at the University of Washington, who wants to understand if the caregiving and less dominant role of female crows gives them a higher capacity for tool use.

While only two species of crow (the New Caledonian crow and the Hawaiian crow) inherently use twigs and sticks as foraging tools, this study also suggests that other crow species, like the American crow, have the neural flexibility to learn to use tools.

A less invasive look at bird brains

Due to their unique behaviors, complex social structures, and reported intelligence, crows have fascinated animal behavioralists for decades. Scientists can study crows’ brains in real time by using 18F-fluorodeoxyglucose (FDG), a radioactive tracer, which the researchers injected into the crows’ brains. They then use positron emission tomography (PET) scans to see which brain areas are activated during different tasks.

“FDG-PET is a method we use to remotely examine activity throughout the entire brain without needing to do any surgeries or implants,” explained Pendergraft. “It’s like [a functional] MRI.” The FDG-PET method is non-invasive, as the crows aren’t required to sit still, which minimizes the stress the crows feel during the experiment.  In the Nature Communications study, Pendergraft and his team ensured the crows were anesthetized before scanning them.

FDG is also used in various medical imaging techniques, such as diagnosing Alzheimer’s disease or screening for cancerous tissue. “Basically, the body treats it as glucose, a substance needed for cells to stay alive,” Pendergraft added. “If a body part is working harder than normal, it’s going to need extra glucose to power the additional activity. This means we can measure relative FDG concentrations within the brain as a proxy for relative brain activity.”

What happens in a crow’s brain when it uses tools?  Read More »

humana-also-using-ai-tool-with-90%-error-rate-to-deny-care,-lawsuit-claims

Humana also using AI tool with 90% error rate to deny care, lawsuit claims

AI, claim denial, coverage, health, humana, insurance, insurance coverage, medicare, medicare advantage, nH Predict, nursing home, post-acute care, Science, unitedhealth / /

AI denials —

The AI model, nH Predict, is the focus of another lawsuit against UnitedHealth.

–

Signage is displayed outside the Humana Inc. office building in Louisville, Kentucky, US, in 2016.

Enlarge / Signage is displayed outside the Humana Inc. office building in Louisville, Kentucky, US, in 2016.

Humana, one the nation’s largest health insurance providers, is allegedly using an artificial intelligence model with a 90 percent error rate to override doctors’ medical judgment and wrongfully deny care to elderly people on the company’s Medicare Advantage plans.

According to a lawsuit filed Tuesday, Humana’s use of the AI model constitutes a “fraudulent scheme” that leaves elderly beneficiaries with either overwhelming medical debt or without needed care that is covered by their plans. Meanwhile, the insurance behemoth reaps a “financial windfall.”

The lawsuit, filed in the US District Court in western Kentucky, is led by two people who had a Humana Medicare Advantage Plan policy and said they were wrongfully denied needed and covered care, harming their health and finances. The suit seeks class-action status for an unknown number of other beneficiaries nationwide who may be in similar situations. Humana provides Medicare Advantage plans for 5.1 million people in the US.

It is the second lawsuit aimed at an insurer’s use of the AI tool nH Predict, which was developed by NaviHealth to forecast how long patients will need care after a medical injury, illness, or event. In November, the estates of two deceased individuals brought a suit against UnitedHealth—the largest health insurance company in the US—for also allegedly using nH Predict to wrongfully deny care.

Humana did not respond to Ars’ request for comment for this story. United Health previously said that “the lawsuit has no merit, and we will defend ourselves vigorously.”

AI model

In both cases, the plaintiffs claim that the insurers use the flawed model to pinpoint the exact date to blindly and illegally cut off payments for post-acute care that is covered under Medicare plans—such as stays in skilled nursing facilities and inpatient rehabilitation centers. The AI-powered model comes up with those dates by comparing a patient’s diagnosis, age, living situation, and physical function to similar patients in a database of 6 million patients. In turn, the model spits out a prediction for the patient’s medical needs, length of stay, and discharge date.

But, the plaintiffs argue that the model fails to account for the entirety of each patient’s circumstances, their doctors’ recommendations, and the patient’s actual conditions. And they claim the predictions are draconian and inflexible. For example, under Medicare Advantage plans, patients who have a three-day hospital stay are typically entitled to up to 100 days of covered care in a nursing home. But with nH Predict in use, patients rarely stay in a nursing home for more than 14 days before claim denials begin.

Though few people appeal coverage denials generally, of those who have appealed the AI-based denials, over 90 percent have gotten the denial reversed, the lawsuits say.

Still, the insurers continue to use the model and NaviHealth employees are instructed to hew closely to the AI-based predictions, keeping lengths of post-acute care to within 1 percent of the days estimated by nH Predict. NaviHealth employees who fail to do so face discipline and firing. ” Humana banks on the patients’ impaired conditions, lack of knowledge, and lack of resources to appeal the wrongful AI-powered decisions,” the lawsuit filed Tuesday claims.

Plaintiff’s cases

One of the plaintiffs in Tuesday’s suit is JoAnne Barrows of Minnesota. On November 23, 2021, Barrows, then 86, was admitted to a hospital after falling at home and fracturing her leg. Doctors put her leg in a cast and issued an order not to put any weight on it for six weeks. On November 26, she was moved to a rehabilitation center for her six-week recovery. But, after just two weeks, Humana’s coverage denials began. Barrows and her family appealed the denials, but Humana denied the appeals, declaring that Barrows was fit to return to her home despite being bedridden and using a catheter.

Her family had no choice but to pay out-of-pocket. They tried moving her to a less expensive facility, but she received substandard care there, and her health declined further. Due to the poor quality of care, the family decided to move her home on December 22, even though she was still unable to use her injured leg, go the bathroom on her own, and still had a catheter.

The other plaintiff is Susan Hagood of North Carolina. On September 10, 2022, Hagood was admitted to a hospital with a urinary tract infection, sepsis, and a spinal infection. She stayed in the hospital until October 26, when she was transferred to a skilled nursing facility. Upon her transfer, she had eleven discharging diagnoses, including sepsis, acute kidney failure, kidney stones, nausea and vomiting, a urinary tract infection, swelling in her spine, and a spinal abscess. In the nursing facility, she was in extreme pain and on the maximum allowable dose of the painkiller oxycodone. She also developed pneumonia.

On November 28, she returned to the hospital for an appointment, at which point her blood pressure spiked, and she was sent to the emergency room. There, doctors found that her condition had considerably worsened.

Meanwhile, a day earlier, on November 27, Humana determined that it would deny coverage of part of her stay at the skilled nursing facility, refusing to pay from November 14 to November 28. Humana said Hagood no longer needed the level of care the facility provided and that she should be discharged home. The family paid $24,000 out-of-pocket for her care, and to date, Hagood remains in a skilled nursing facility.

Overall, the patients claim that Humana and UnitedHealth are aware that nH Predict is “highly inaccurate” but use it anyway to avoid paying for covered care and make more profit. The denials are “systematic, illegal, malicious, and oppressive.”

The lawsuit against Humana alleges breach of contract, unfair dealing, unjust enrichment, and bad faith insurance violations in many states. It seeks damages for financial losses and emotional distress, disgorgement and/or restitution, and to have Humana barred from using the AI-based model to deny claims.

Humana also using AI tool with 90% error rate to deny care, lawsuit claims Read More »

every-homeopathic-eye-drop-should-be-pulled-off-the-market,-fda-says

Every homeopathic eye drop should be pulled off the market, FDA says

eye drops, fda, health, homeopathic, infection, Science, Vision / /

don’t risk it —

Eye drops are uniquely risky because the eye is an immune-privileged site.

–

Young man applying eye drops.

This year has been marked by many terrifying things, but perhaps the most surprising of the 2023 horrors was … eye drops.

The seemingly innocuous teeny squeeze bottle made for alarming headlines numerous times during our current revolution around the sun, with lengthy lists of recalls, startling factory inspections, and ghastly reports of people developing near-untreatable bacterial infections, losing their eyes and vision, and dying.

Recapping this unexpected threat to health, the Food and Drug Administration on Tuesday released an advisory titled “What You Should Know about Eye Drops” in hopes of keeping the dangers of this year from leaking into the next. Among the notable points from the regulator was this stark pronouncement: No one should ever use any homeopathic ophthalmic products, and every single such product should be pulled off the market.

The point is unexpected, given that none of the high-profile infections and recalls this year involved homeopathic products. But, it should be welcomed by any advocates of evidence-based medicine.

Homeopathy is an 18th century pseudoscience that produces bogus remedies that work no better than a placebo and, if prepared improperly, can be toxic, even deadly. The practice relies on two false principles: the  “law of similars,” aka “like cures like,” meaning a substance that causes a specific symptom in a healthy person can treat conditions and diseases that involve that same symptom, and the “law of infinitesimals,” which states that diluting the substance renders it more potent. As such, homeopathic products begin with toxic substances that are then extremely diluted—often into oblivion—in a ritualistic procedure. Some homeopaths hold that water molecules can have “memory.”

Clear risks

In the US, these products are marketed as legitimate treatments and sold alongside evidence-based treatments (though consumer advocates are trying to change that). The reason this is allowed for now is because of a regulatory quirk: Based on the 1938 Food, Drug, and Cosmetic Act, homeopathic products are generally considered exempt from pre-market FDA safety and efficacy reviews as long as the active ingredient in the product is included in the Homeopathic Pharmacopoeia, a list of substances approved by homeopaths.

In recent years, the FDA and the Federal Trade Commission have cracked down on homeopathic products, though. And it seems from today’s advisory that the FDA is not holding back on homeopathic products for the eyes. The regulator notes that any products meant for the eye “pose a heightened risk of harm” because the eyes are an immune-privileged site in the body. That is, innate immune responses are restrained in the eye to prevent damaging inflammation, which could threaten vision. “Any drug used in the eyes must be sterile to reduce the risk of infection,” the FDA said.

But whether or not homeopathic eye drops are labeled as sterile doesn’t seem to matter to the FDA. The regulator cautions: “Do not use ophthalmic products that: Are labeled as homeopathic, as these products should not be marketed.” Their lack of pre-market safety and efficacy reviews appears to be enough to warrant avoidance.

The FDA also cautions consumers not to use any over-the-counter eye drop product that claims to treat glaucoma, cataracts, retinopathy, or macular degeneration because there are simply no actual over-the-actual treatments for these conditions. If a non-prescription product claims this, you can assume it’s bogus and avoid it. Consumers should also avoid anything that includes Methylsulfonylmethane (MSM), which is illegally sold in the US, and anything with silver sulfate or argentum because these can permanently change the white color of your eyes.

Every homeopathic eye drop should be pulled off the market, FDA says Read More »

cvs,-rite-aid,-walgreens-hand-out-medical-records-to-cops-without-warrants

CVS, Rite Aid, Walgreens hand out medical records to cops without warrants

Amazon, cops, cvs, health, health privacy, HHS, HIPAA, law enforcement, Medical records, pharmacy, Policy, prescription drugs, rite aid, Science, Walgreens, warrant / /

prescription for privacy —

Lawmakers want HHS to revise health privacy law to require warrants.

–

CVS, Rite Aid, Walgreens hand out medical records to cops without warrants

All of the big pharmacy chains in the US hand over sensitive medical records to law enforcement without a warrant—and some will do so without even running the requests by a legal professional, according to a congressional investigation.

The revelation raises grave medical privacy concerns, particularly in a post-Dobbs era in which many states are working to criminalize reproductive health care. Even if people in states with restrictive laws cross state lines for care, pharmacists in massive chains, such as CVS, can access records across borders.

Lawmakers noted the pharmacies’ policies for releasing medical records in a letter dated Tuesday to the Department of Health and Human Services (HHS) Secretary Xavier Becerra. The letter—signed by Sen. Ron Wyden (D-Ore.), Rep. Pramila Jayapal (D-Wash.), and Rep. Sara Jacobs (D-Calif.)—said their investigation pulled information from briefings with eight big prescription drug suppliers.

They include the seven largest pharmacy chains in the country: CVS Health, Walgreens Boots Alliance, Cigna, Optum Rx, Walmart Stores, Inc., The Kroger Company, and Rite Aid Corporation. The lawmakers also spoke with Amazon Pharmacy.

All eight of the pharmacies said they do not require law enforcement to have a warrant prior to sharing private and sensitive medical records, which can include the prescription drugs a person used or uses and their medical conditions. Instead, all the pharmacies hand over such information with nothing more than a subpoena, which can be issued by government agencies and does not require review or approval by a judge.

Three pharmacies—CVS Health, The Kroger Company, and Rite Aid Corporation—told lawmakers they didn’t even require their pharmacy staff to consult legal professionals before responding to law enforcement requests at pharmacy counters. According to the lawmakers, CVS, Kroger, and Rite Aid said that “their pharmacy staff face extreme pressure to immediately respond to law enforcement demands and, as such, the companies instruct their staff to process those requests in store.”

The rest of the pharmacies—Amazon, Cigna, Optum Rx, Walmart, and Walgreens Boots Alliance—at least require that law enforcement requests be reviewed by legal professionals before pharmacists respond. But, only Amazon said it had a policy of notifying customers of law enforcement demands for pharmacy records unless there were legal prohibitions to doing so, such as a gag order.

HIPAA and transparency

The lawmakers note that the pharmacies aren’t violating regulations under the Health Insurance Portability and Accountability Act (HIPAA). The pharmacies pointed to language in HIPAA regulations that allow health care providers, including pharmacists, to provide medical records if required by law, with subpoenas being a sufficient legal process for such a request. However, the lawmakers note that the HHS has discretion in determining the legal standard here—that is, it has the power to strengthen the regulation to require a warrant, which the lawmakers say it should do.

“We urge HHS to consider further strengthening its HIPAA regulations to more closely align them with Americans’ reasonable expectations of privacy and Constitutional principles,” the three lawmakers wrote.

They also pushed for pharmacies to do better, encouraging them to follow the lead of tech companies. “Pharmacies can and should insist on a warrant, and invite law enforcement agencies that insist on demanding patient medical records with solely a subpoena to go to court to enforce that demand. The requirement for a warrant is exactly the approach taken by tech companies to protect customer privacy.” The trio noted that Google, Microsoft, and Yahoo have since 2010 required law enforcement to have a warrant to obtain customers’ emails.

Also noting tech companies’ lead, the lawmakers encouraged pharmacies to publish annual transparency reports. In the course of the investigation, only CVS Health said it planned to do so.

“Americans deserve to have their private medical information protected at the pharmacy counter and a full picture of pharmacies’ privacy practices, so they can make informed choices about where to get their prescriptions filled,” the lawmakers wrote.

For now, HIPAA regulations grant patients the right to know who is accessing their health records. But, to do so, patients have to specifically request that information—and almost no one does that. “Last year, CVS Health, the largest pharmacy in the nation by total prescription revenue, only received a single-digit number of such consumer requests,” the lawmakers noted.

“The average American is likely unaware that this is even a problem,” the lawmakers said.

CVS, Rite Aid, Walgreens hand out medical records to cops without warrants Read More »